PharmAla signs distribution agreement for its MDMA drug in the U.S. | Where to buy Skittles Moonrock online

Learn how to order CBD Vape online. TOP QUALITY GRADE A++

Cannabyss Inc. is the best place online to buy top quality weed, cannabis, vape, marijuana and CBD products. Get your borderless orders delivered at the pickup spot with ease. Top Grade products for client satisfaction.

👉 Click here to Visit our shop! 🛒

PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTC: MDXXF) announced that it has contracted with a third-party logistics company specializing in pharmaceutical products to act as its US clinical trial distribution partner. PharmAla makes novel MDXX class molecules including its LaNeo MDMA.

However, the name of PharmAla’s logistics partner is being withheld at the company’s request. According to the company statement, the partner will act on PharmAla’s behalf only in the storage and directed distribution of PharmAla’s products.

“PharmAla has noted over the past months that US-Canada cross-border shipping uncertainty has increased. This uncertainty is negatively impacting our numerous clinical trial customers in the United States,” said Nicholas Kadysh, CEO, of PharmAla Biotech. “As our volume of business in the US grows, we are always looking for ways to optimize our work; with the potential imposition of tariff barriers, we believe that this is even more important. We are pleased to have contracted with an exceptionally capable partner to store and distribute our LaNeo clinical trial materials on behalf of both ourselves and our US clients.”

The company told investors that its agreement with this partner should provide for a streamlined warehoused, GMP-compliant supply of LaNeo MDMA for all current clients already contracted. It is also expected to provide certainty against import/export risks for future clients seeking to purchase LaNeo MDMA for clinical trials in the United States.

Last week, PharmAla informed the market that it successfully completed an international shipment of LaNeo MDMA to the University of Washington, USA. The company has been fulfilling orders for human research studies in the U. S. that have chosen to use its pharmaceutical-grade LaNeo MDMA capsules for their clinical research.

Tariff worries

Pharmala told investors that it was “Regrettable that important US research is detrimentally impacted by tariffs, and calls for all investigational drug products destined for US-funded health research studies at US institutions to be exempt from tariffs. By global convention, all investigational drugs destined for clinical research are usually shipped tariff-free.”

COO Dr. Shane Morris said, “It has become apparent that US-Canada cross-border trade uncertainty is an ongoing risk for clients. As a result, the PharmAla team is working hard to mitigate such uncertainty, and we look forward to announcing a solution soon.”